David A. Siegel Ventyx Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 800,800 shares of VTYX stock, worth $1.38 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
800,800
Previous 465,400
72.07%
Holding current value
$1.38 Million
Previous $1.01 Million
72.88%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding VTYX
# of Institutions
134Shares Held
55.2MCall Options Held
81.4KPut Options Held
148K-
Black Rock Inc. New York, NY4.77MShares$8.21 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.48MShares$7.71 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.27MShares$7.35 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY4.05MShares$6.96 Million3.31% of portfolio
-
Ubs Group Ag3.78MShares$6.51 Million0.0% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $97.2M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...